Nibix (Imatinib)

Imatinib acts on malignant cells driven by BCR‑ABL, c‑KIT or PDGFR signaling pathways, providing targeted therapy for specific cancers.

• Chronic myeloid leukemia (CML): reduces leukemic cell proliferation and improves long‑term survival.
• Philadelphia chromosome‑positive acute lymphoblastic leukemia (Ph+ ALL): achieves remission by inhibiting BCR‑ABL positive blasts.
• Gastrointestinal stromal tumor (GIST): blocks tumor growth driven by c‑KIT or PDGFR mutations.

• Imatinib selectively inhibits the ATP‑binding site of BCR‑ABL tyrosine kinase as well as the related kinases c‑KIT and platelet‑derived growth factor receptor (PDGFR). By blocking these enzymes, it prevents downstream phosphorylation events that drive uncontrolled cell division, thereby suppressing proliferation of malignant hematopoietic and stromal cells.

Imatinib is associated with a range of adverse reactions that vary in frequency and severity.

Common Side Effects

• Nausea and vomiting
• Edema, especially peripheral
• Muscle cramps or pain
• Fatigue or weakness
• Diarrhea
• Rash or mild skin irritation

Serious or Rare Side Effects

• Severe hepatotoxicity (elevated liver enzymes, jaundice)
• Neutropenia or severe leukopenia
• Thrombocytopenia leading to bleeding risk
• Cardiac failure or reduced left‑ventricular function
• Pulmonary hypertension
• Stevens‑Johnson syndrome or toxic epidermal necrolysis

Before initiating therapy, clinicians should evaluate baseline organ function and monitor patients regularly.

• Monitor blood counts: perform routine CBC to detect cytopenias.
• Assess liver function: check transaminases and bilirubin periodically.
• Evaluate cardiac status: obtain baseline ECG and echocardiogram if risk factors exist.
• Avoid use in patients with known hypersensitivity to imatinib or its excipients; discontinue if severe reaction occurs.
• Store at room temperature: keep in the original container, protect from moisture and light.

Imatinib may interact with several co‑administered medicines, altering its plasma concentration or toxicity profile.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib exposure.
• Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic levels.
• Antacids containing aluminum or magnesium: can decrease oral absorption.

Moderate Interactions (Monitor Closely)

• Warfarin: may potentiate anticoagulant effect; monitor INR.
• Systemic corticosteroids: may enhance fluid retention and edema.
• Live vaccines: efficacy may be reduced; consider timing of vaccination.